Ausgehend von der Hypothese, dass ein erhöhter linksatrialer Druck (LA-Druck) pathophysiologisch bedeutsam bei der Herzinsuffizienz mit erhaltener Ejektionsfraktion ist, wurde ein Verfahren zur Senkung des LA-Drucks durch einen katheterbasierten implantierbaren interatrialen Shunt entwickelt. Bisher vorliegende Studien zeigen, dass dies sicher ist und den LA- und pulmonalarteriellen Druck anhaltend senkt. Eine anhaltend verbesserte Hämodynamik der Patienten unter Belastung und eine verbesserte klinische Symptomatik gehen damit einher.
Literatur
Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28
Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment on exercise to- lerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 2011;57:1676–86
Pandey A, Parashar A, Kumbhani D et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40
Hasenfuß G, Burkhoff D, Kaye DM. A Shunt Device to Reduce Left Atrial Pressure. Cardiovasc Med. 2018, in press
Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnomral right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016:37:3293–302
Dorfs S, Zeh W, Hochholzer W et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3103–12
Hasenfuß G, Hayward C, Burkhoff D et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicenter, open-label, single-arm, phase 1 trial. Lancet. 2016;387:1298–304
Del Trigo M, Bergeron S, Bernier M et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387:1290–97
Feldman T, Mauri L, Kahwash R et al. A transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I): A phase 2, Randomized, Sham-controlled trial. Circulation. 2017 Nov 15; https://doi.org/10.1161/CIRCULATIONAHA.117.032094
Kaye DM, Hasenfuß G, Neuzil P et al. One-year outcomes after transcatheter insertion of an interatrial shunt device fort he management of heart failure with preserved ejection fraction. Cir Heart Fail. 2016;9:e003662; https://doi.org/10.1161/CIR-CHEARTFAILURE.116.003662
Adamson PB, Abraham WT, Bourge RC et al. Wireless pulmonary artery pressure monitoring ruides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935–44
Zile MR, Bennett TD, El Hajj S et al. Intracardiac pressures measured using an implantable hemodynamic monitor — Relationship to mortality in patients with chronic heart failure. Circ Heart Fail. 2017;10:e003594; https://doi.org/10.1161/CIRCHEARTFAILURE.116.003594
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasenfuß, G. Vorhofseptum-Shunt bei schwerer diastolischer Herzinsuffizienz. CV 18, 39–42 (2018). https://doi.org/10.1007/s15027-018-1340-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15027-018-1340-0